Authors: WANG JP UNADKAT JD MCNAMARA S OSULLIVAN TA SMITH AL TRAGER WF RAMSEY B

Citation: Jp. Wang et al., DISPOSITION OF DRUGS IN CYSTIC-FIBROSIS .11. IN-VIVO ACTIVITY OF CYTOCHROME-P450 ISOFORMS INVOLVED IN THE METABOLISM OF (R)-WARFARIN (INCLUDING P450 3A4) IS NOT ENHANCED IN CYSTIC-FIBROSIS, Clinical pharmacology and therapeutics, 55(5), 1994, pp. 528-534

Authors: WANG JP UNADKAT JD MCNAMARA S OSULLIVAN TA SMITH AL TRAGER WF RAMSEY B

Citation: Jp. Wang et al., IN-VIVO CYTOCHROME-P450 ACTIVITY IN CYSTIC-FIBROSIS (CF) AS PROBED BY(R)-WARFARIN, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 180-180

Authors: WANG JP UNADKAT JD ALHABET SMH OSULLIVAN TA WILLIAMSWARREN J SMITH AL RAMSEY B

Citation: Jp. Wang et al., DISPOSITION OF DRUGS IN CYSTIC-FIBROSIS .4. MECHANISMS FOR ENHANCED RENAL CLEARANCE OF TICARCILLIN, Clinical pharmacology and therapeutics, 54(3), 1993, pp. 293-302

Authors: OSULLIVAN TA WANG JP UNADKAT JD ALHABET SMH TRAGER WF SMITH AL MCNAMARA S AITKEN ML

Citation: Ta. Osullivan et al., DISPOSITION OF DRUGS IN CYSTIC-FIBROSIS .5. IN-VIVO CYP2C9 ACTIVITY AS PROBED BY (S)-WARFARIN IS NOT ENHANCED IN CYSTIC-FIBROSIS, Clinical pharmacology and therapeutics, 54(3), 1993, pp. 323-328